Govt Support To Speed Corestem’s Lupus Cell Therapy
This article was originally published in PharmAsia News
Another South Korean biotech firm is benefiting from the government's ongoing support for the sector. New financial assistance is set to accelerate Corestem's first clinical trials with a novel stem cell therapy for lupus, which is said to be showing the fastest commercial development pace among similar treatments.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.